QGEN WeeklyNYSE:QGEN weekly gave a bullish engulfing at the 5 and 20 EMA crossover along with MACD crossing up. This is after a triple bottom process around $46.
Next report date
Report period
Q1 2024
EPS estimate
0.41EUR
Revenue estimate
420.68 MEUR
1.395EUR
309.22 MEUR
1.78 BEUR
220.30 M
About Qiagen N.V.
Sector
Industry
CEO
Thierry Bernard
Website
Headquarters
Venlo
Employees (FY)
5.97 K
Founded
1996
ISIN
NL0015001WM6
FIGI
BBG01K3WJM56
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.
Qiagen NV 🧙Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates over 85% of its revenue from consumables with the bal
QGEN (Qiagen N.V) - Bullish quarterly outlookQiagen N.V
Qiagen NV produces biomedical and genetic products, products for separating and purifying nucleic acids for gene-based drug screening, nucleic acid-based clinical diagnostics, genetic vaccination and gene therapy.
Analysis/Commentary
Strong EPS and Sales Growth Y-on-Y
Based on the stu
The Perception of QIAGEN DailyHello traders, QIAGEN is in a bullish push with sellers rejecting a buy candle and low bull volume. On the TIMEFRAME 30 15 Min a bull hammer move and in the 5 1 Min is in bullish continuity. Great likelihood of starting on the next high which corresponds to the middle of the median. And if the buyer
Great Look for QGENLoving this setup. QGEN has struggled with this level for over a year. Recently it has consolidated with very tight price action and low volume at the highs. Volume has started to come in over the last two days as it looks to make a run for it. A good swing trade candidate. A move below $41 would ha
Shot in the darkThis stock has a ton of positive hype surrounding it because of the 'rona. Nonetheless, the chart screams institutional liquidation to me. This is a gut feeling and I could easily be wrong a hundred fold. Something doesn't fit right and makes me I'm painting a picture in my head where institutional
Hi my name is: QiagenHello People,
Qiagen should create a normal flat. Therfore the wave C is coming an I wait for it.
May the foce be with you.
QIAGEN NV (QGEN) - GAP-FILL TRADEEntry Point: When price crosses above 50 DMA (blue line). This allows prices to take over 50 Week MA and 20 Month MA first.
Profit Taking: Around $40.50 when gap about to close
Stop Loss: When price crosses below 20 DMA to minimize heavy loss. For me, I will exit when price crosses below the support
Qiagen NV Bullish perspective Coronavirus Stock $qgenQGEN announced the shipping of its latest QIAstat-Dx Respiratory Panel 2019-nCoV test kit to four hospitals in China for evaluation purposes. The latest test kit helps detect the novel coronavirus SARS-CoV-2, thus adding rapid Sample to Insight syndromic testing to the company’s molecular testing so
Textbook SeahorseCouldn't ask for a better seahorse.
SWOOP-bust.
Where else you gonna put your offspring?
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 1QGEN is 38.935 EUR — it has increased by 0.19% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange QIAGEN stocks are traded under the ticker 1QGEN.
QIAGEN is going to release the next earnings report on Apr 29, 2024. Keep track of upcoming events with our Earnings Calendar.
1QGEN stock is 0.44% volatile and has beta coefficient of 1.01. Check out the list of the most volatile stocks — is QIAGEN there?
1QGEN earnings for the last quarter are 0.49 EUR per share, whereas the estimation was 0.47 EUR resulting in a 3.95% surprise. The estimated earnings for the next quarter are 0.50 EUR per share. See more details about QIAGEN earnings.
QIAGEN revenue for the last quarter amounts to 450.19 M EUR despite the estimated figure of 444.42 M EUR. In the next quarter revenue is expected to reach 453.70 M EUR.
Yes, you can track QIAGEN financials in yearly and quarterly reports right on TradingView.
1QGEN stock has risen by 4.54% compared to the previous week, the month change is a 1.84% fall, over the last year QIAGEN has showed a 5.00% increase.
1QGEN net income for the last quarter is 88.48 M EUR, while the quarter before that showed 73.62 M EUR of net income which accounts for 20.20% change. Track more QIAGEN financial stats to get the full picture.
Today QIAGEN has the market capitalization of 8.62 B, it has increased by 4.51% over the last week.
Like other stocks, 1QGEN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade QIAGEN stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 29, 2024, the company has 5.97 K employees. See our rating of the largest employees — is QIAGEN on this list?
We've gathered analysts' opinions on QIAGEN future price: according to them, 1QGEN price has a max estimate of 56.12 EUR and a min estimate of 39.28 EUR. Read a more detailed QIAGEN forecast: see what analysts think of QIAGEN and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. QIAGEN EBITDA is 589.44 M EUR, and current EBITDA margin is 33.10%. See more stats in QIAGEN financial statements.